Last reviewed · How we verify
A Study of Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib demonstrate excellent effect on the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, patients who are initially sensitive to the drugs eventually become resistance. Apatinib is a highly selective VEGFR2 inhibitor and reduces the angiogenesis of tumor efficiently. In this study, the investigators aim to explore the efficacy and reasonable dosage of apatinib combining with EGFR-TKI in advanced non-squamous non-small cell lung cancer with EGFR-TKI resistance.
Details
| Lead sponsor | Peking University Third Hospital |
|---|---|
| Phase | Phase 1 |
| Status | UNKNOWN |
| Enrolment | 30 |
| Start date | 2016-05 |
| Completion | 2019-10 |
Conditions
- Nonsmall Cell Lung Cancer
Interventions
- Apatinib Mesylate Tablets
- EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)
Primary outcomes
- Optimal Dosage — 9 months
Optimal dosage of Apatinib which combine with EGFR-TKIs - Progression free survival — 24 months
PFS is evaluated in 24 months since the treatment begin
Countries
China